Refining the Treatment of NSCLC According to Histological and Molecular Subtypes|
The authors provide an overview of the key developments in the treatment of non-small-cell lung cancer (NSCLC), and discusses potential strategies to further optimize therapy by targeting disease subtypes. [Nat Rev Clin Oncol] Abstract
Circadian Clock Coupled Lung Cellular and Molecular Functions in Chronic Airway Diseases
The authors review current understanding of clock-controlled cellular and molecular functions in the lungs, the impact of clock dysfunction in chronic airway disease and the response of the pulmonary clock to different environmental perturbations. Further, they discuss the evidence for candidate signaling pathways, such as the sirtuin 1-BMAL1-REV-ERBα axis as novel target for chronopharmacological management of chronic airway diseases. [Am J Respir Cell Mol Biol]
Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.
Pivotal Data for Roche Medicines in Lung and Blood Cancers to Be Presented|
Roche announced that data from ten of its approved cancer medicines and ten of its investigational medicines will be presented. These data demonstrate the strength of Roche’s oncology pipeline, particularly in cancer immunotherapy and personalized medicine. [Press release from Roche Ltd. discussing research to be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago]
Boehringer Ingelheim Showcases Expanding Presence in Lung Cancer with New Data Including Presentation of Gilotrif® (Afatinib) Overall Survival Results for Squamous Cell Carcinoma of the Lung
Boehringer Ingelheim announced that the latest data from its oncology portfolio will be presented. A total of nine abstracts, including new data for afatinib and nintedanib, will emphasize the growing presence of Boehringer Ingelheim in lung and other cancer types. [Press release from Boehringer Ingelheim GmbH discussing research to be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago]
PharmaMar Announces New Advances in Oncology for Its Compounds YONDELIS® and PM1183 in Small Cell Lung Cancer, Soft Tissue Sarcoma, and Mesothelioma
PharmaMar announced that it will present several clinical studies to showcase the data obtained in various tumor types, including SCLC, soft tissue sarcoma and mesothelioma. [Press release from PharmaMar discussing research to be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago] Press Release
Astellas Announces New Data in Advanced Prostate and Breast Cancers, Acute Myeloid Leukemia, and Lung and Renal Cancers to Be Presented
Astellas announced several abstracts across multiple cancers that will be presented. [Press release from Astellas Pharma US, Inc. discussing research to be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago] Press Release
From our sponsor: 3D intestinal organoid culture is made easy with IntestiCult™. Request a sample.